Canning Jack S, Laucirica Daniel R, Ling Kak-Ming, Nicol Mark P, Stick Stephen M, Kicic Anthony
Division of Infection and Immunity, School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Nedlands, WA, Australia.
Wal-Yan Respiratory Research Centre, The Kids Research Institute Australia, The University of Western Australia, Nedlands, WA, Australia.
Front Microbiol. 2024 Oct 18;15:1476041. doi: 10.3389/fmicb.2024.1476041. eCollection 2024.
complex is a cause of serious lung infections in people with cystic fibrosis, exhibiting extremely high levels of antimicrobial resistance. These infections are difficult to treat and are associated with high morbidity and mortality. With a notable lack of new antibiotic classes currently in development, exploring alternative antimicrobial strategies for complex is crucial. One potential alternative seeing renewed interest is the use of bacteriophage (phage) therapy. This review summarises what is currently known about complex in cystic fibrosis, as well as challenges and insights for using phages to treat complex lung infections.
[病原体名称]复合体是囊性纤维化患者严重肺部感染的病因，表现出极高的抗菌耐药性。这些感染难以治疗，且与高发病率和死亡率相关。鉴于目前正在研发的新型抗生素类别明显不足，探索针对[病原体名称]复合体的替代抗菌策略至关重要。一种重新引起人们兴趣的潜在替代方法是使用噬菌体疗法。本综述总结了目前关于囊性纤维化中[病原体名称]复合体的已知情况，以及使用噬菌体治疗[病原体名称]复合体肺部感染的挑战和见解。
